Results 141 to 150 of about 5,946,577 (342)

Aberrant expression of nuclear prothymosin α contributes to epithelial‐mesenchymal transition in lung cancer

Molecular Oncology, EarlyView.
Nuclear prothymosin α inhibits epithelial‐mesenchymal transition (EMT) in lung cancer by increasing Smad7 acetylation and competing with Smad2 for binding to SNAI1, TWIST1, and ZEB1 promoters. In early‐stage cancer, ProT suppresses TGF‐β‐induced EMT, while its loss in the nucleus in late‐stage cancer leads to enhanced EMT and poor prognosis.
Liyun Chen, Chung‐Teng Wang, Jia‐Ming Chang, Ai‐Li Shiau, Gia‐Shing Shieh, Yau‐Lin Tseng, Yi‐Ting Yen, Tang‐Hsiu Huang, Li‐Hsin Cheng, Yu‐Chih Wu, Chao‐Liang Wu, Bing‐Hua Su, Pensee Wu   +12 more
wiley   +1 more source

Protocol for the creation and characterization of SARS-CoV-2 variant testing panels using remnant clinical samples for diagnostic assay testing

STAR Protocols
Summary: The emergence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Alpha variant in 2020 demonstrated the need for reanalysis of diagnostic tests to ensure detection of emerging variants.
Leda Bassit, Heather B. Bowers, Morgan Greenleaf, Courtney Sabino, Eric Lai, Grace Yu, Anne Piantadosi, Ethan Wang, William O’Sick, Kaleb McLendon, Julie A. Sullivan, Raymond F. Schinazi, Gregory L. Damhorst, Wilbur Lam, Anuradha Rao   +14 more
doaj   +1 more source

Point-of-Care Testing/Point-of-Care Testing

LaboratoriumsMedizin, 2002
Angelika Heinschink, Mathias Müller
openaire   +2 more sources

The Rise and Fall of i-STAT Point-of-Care Blood Gas Testing in an Acute Care Hospital [PDF]

, 2000
Valerie L. Ng, R Kraemer, Carol Hogan, Doug Eckman, Mark S Siobal   +4 more
openalex   +1 more source

Early metastasis is characterized by Gr1+ cell dysregulation and is inhibited by immunomodulatory nanoparticles

Molecular Oncology, EarlyView.
Breast cancer metastasis is associated with myeloid cell dysregulation and the lung‐specific accumulation of tumor‐supportive Gr1+ cells. Gr1+ cells support metastasis, in part, through a CHI3L1‐mediated mechanism, which can be targeted and inhibited with cargo‐free, polymeric nanoparticles.
Jeffrey A. Ma, Sophia M. Orbach, Kate V. Griffin, Kathryn Kang, Yining Zhang, Rebecca S. Pereles, Ian A. Schrack, Guillermo Escalona, Jacqueline S. Jeruss, Lonnie D. Shea   +9 more
wiley   +1 more source

…About point-of-care testing [PDF]

, 2000
EDWINA A. McCONNELL
openalex   +1 more source

Detecting homologous recombination deficiency for breast cancer through integrative analysis of genomic data

Molecular Oncology, EarlyView.
This study develops a semi‐supervised classifier integrating multi‐genomic data (1404 training/5893 validation samples) to improve homologous recombination deficiency (HRD) detection in breast cancer. Our method demonstrates prognostic value and predicts chemotherapy/PARP inhibitor sensitivity in HRD+ tumours.
Rong Zhu, Katherine Eason, Suet‐Feung Chin, Paul A. W. Edwards, Raquel Manzano Garcia, Richard Moulange, Jia Wern Pan, Soo Hwang Teo, Sach Mukherjee, Maurizio Callari, Carlos Caldas, Stephen‐John Sammut, Oscar M. Rueda   +12 more
wiley   +1 more source

Randomized comparison of in vivo performance of two point-of-care tear film osmometers

Clinical Ophthalmology, 2017
Jerry Nolfi, Barbara Caffery Toronto Eye Care Optometric Clinic, Toronto, ON, Canada Purpose: To compare the in vivo precision of two commercially available point-of-care osmometers among normal subjects with no dry eye disease. Methods: Twenty healthy
Nolfi J, Caffery B
doaj  

Room C, 10/16/2000 9: 00 AM - 11: 00 AM (PS) Evaluation of the Ultegra®, Point-of-Care Platelet Function Instrument during Cardiac Surgery [PDF]

, 2000
Linda Shore‐Lesserson, Rao Saleem, Marc E. Stone, Robert S. Hillman, George Despotis   +4 more
openalex   +1 more source

Landscape of BRAF transcript variants in human cancer

Molecular Oncology, EarlyView.
We investigate the annotation of BRAF variants, focusing on protein‐coding BRAF‐220 (formerly BRAF‐reference) and BRAF‐204 (BRAF‐X1). The IsoWorm pipeline allows us to quantify these variants in human cancer, starting from RNA‐sequencing data. BRAF‐204 is more abundant than BRAF‐220 and impacts patient survival.
Maurizio S. Podda, Danilo Tatoni, Gianluca Mattei, Alberto Magi, Romina D'Aurizio, Laura Poliseno   +5 more
wiley   +1 more source